Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

pS363-DOP (phospho-∂-Opioid Receptor Antibody)

Citations
$ 375.00 *

Prices plus VAT plus shipping costs

Ready to ship today,
Delivery time appr. 5-8 days

  • 7TM0317B
  • 100 µl
  • Rabbit
Serine363 (S363) is the primary phosphorylation site in a hierarchical phosphorylation cascade... more

Serine363 (S363) is the primary phosphorylation site in a hierarchical phosphorylation cascade of the delta-opioid receptor (DOP). The pS363-DOP antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. S363 phosphorylation is a key regulator of DOP desensitization, β-arrestin recruitment and internalization. The pS363-DOP antibody can detect phosphorylated DOP in mouse brain in vivo. The pS363-DOP antibody can by used for detection of the subcellular location of phosphorylated DOP by immunocytochemistry.

  Alternative Names DOP, OPRD1, δ-Opioid Receptor IUPHAR Target ID... more

 

Alternative Names DOP, OPRD1, δ-Opioid Receptor
IUPHAR Target ID  317
UniProt ID  P41143 (human) P32300 (mouse) P33533 (rat)
Western Blot (WB)  1:1000
Species Reactivity   Human, Mouse, Rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Immunogen A synthetic phosphopeptide derived from human DOP around the phosphorylation site of Ser363
Form  Liquid
Purification Antigen affinity chromatography
Storage buffer Dulbecco's PBS, pH 7.4, with 150 mM NaCl, 0.02% sodium azide
Storage conditions short-term 4°C, long-term -20°C
Figure 1. Agonist-induced Serine363 phosphorylation of the δ-Opioid receptor. Upper panel,... more

Figure 1. Agonist-induced Serine363 phosphorylation of the δ-Opioid receptor. Upper panel, HEK293 cells stably expressing the δ-Opioid Receptor (DOP) were either not exposed or exposed to 10 μM DPDPE ([D-Pen2,D-Pen5]-enkephalin) or 0.1 μM PMA (Phorbol 12-Myristate 13-Acetate) for 30 minutes. Cells were lysed and immunoblotted with the anti-pS363-DOP antibody (7TM0317B) at a dilution of 1:1000. Lower panel, blot was stripped and reprobed with a phosphorylation-independent anti-DOP antibody to confirm equal loading of the gel.

Figure 2. Analysis of dose-dependent δ-Opioid Receptor phosphorylation using two phosphosite-specific antibodies. Upper two panels, HEK293 cells stably expressing the δ-Opioid Receptor (DOP) were either not exposed or exposed to increasing concentrations of selective δ-opioid receptor agonist SNC80 ranging from 1 nM to 10 μM for 30 minutes. Cells were lysed and immunoblotted with the anti-pT361-DOP antibody (7TM0317A) or anti-pS363-DOP antibody (7TM0317B) at a dilution of 1:1000. Lower panel, blot was stripped and reprobed with a phosphorylation-independent anti-DOP antibody to confirm equal loading of the gel.

Figure 3. Immunocytochemical identification of Serine363 phosphorylation of the δ-Opioid Receptor. HEK293 cells stably expressing the δ-Opioid Receptor (DOP) were either not exposed or exposed to 10 μM DPDPE ([D-Pen2,D-Pen5]-enkephalin) for 2, 5 or 30 min and immunocytochemically stained with the anti-pS363-DOP antibody (7TM0317B) at a dilution of 1:200. Note, Serine363-phosphorylated DOP receptors were not detectable in untreated cells (0 min). Serine363-phosphorylated DOP receptors were seen at the plasma membrane (2 min) and with increased time of stimulation (5 and 30 min) as perinuclear clusters.

Mann A, Liebetrau S, Klima M, Dasgupta P, Massotte D, Schulz S. Agonist-induced... more
Read, write and discuss reviews... more
Customer evaluation for "pS363-DOP (phospho-∂-Opioid Receptor Antibody)"
Write an evaluation
Evaluations will be activated after verification.

The fields marked with * are required.

Recently viewed